TWI924837B - 用於治療子宮漿液性癌之wee1化合物 - Google Patents

用於治療子宮漿液性癌之wee1化合物

Info

Publication number
TWI924837B
TWI924837B TW111113723A TW111113723A TWI924837B TW I924837 B TWI924837 B TW I924837B TW 111113723 A TW111113723 A TW 111113723A TW 111113723 A TW111113723 A TW 111113723A TW I924837 B TWI924837 B TW I924837B
Authority
TW
Taiwan
Prior art keywords
administered
therapeutically effective
effective dose
usc
item
Prior art date
Application number
TW111113723A
Other languages
English (en)
Chinese (zh)
Other versions
TW202304455A (zh
Inventor
飛利浦 普特
迪米崔歐斯 沃利歐提斯
馬可斯 羅德里奎茲 維安那
費南多 杜奈特
鍾 彼特勞斯 魯德夫 德
亞玫德 亞迪 沙曼塔
凱文 杜安 班納
琴華 黃
Original Assignee
美商瑞卡瑞恩Ip控股有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商瑞卡瑞恩Ip控股有限責任公司 filed Critical 美商瑞卡瑞恩Ip控股有限責任公司
Publication of TW202304455A publication Critical patent/TW202304455A/zh
Application granted granted Critical
Publication of TWI924837B publication Critical patent/TWI924837B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
TW111113723A 2021-04-12 2022-04-11 用於治療子宮漿液性癌之wee1化合物 TWI924837B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163174004P 2021-04-12 2021-04-12
US202163174005P 2021-04-12 2021-04-12
US63/174,005 2021-04-12
US63/174,004 2021-04-12

Publications (2)

Publication Number Publication Date
TW202304455A TW202304455A (zh) 2023-02-01
TWI924837B true TWI924837B (zh) 2026-05-11

Family

ID=83640600

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111113723A TWI924837B (zh) 2021-04-12 2022-04-11 用於治療子宮漿液性癌之wee1化合物

Country Status (7)

Country Link
US (1) US20240197743A1 (cg-RX-API-DMAC7.html)
EP (1) EP4322958A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517085A (cg-RX-API-DMAC7.html)
AU (1) AU2022259496A1 (cg-RX-API-DMAC7.html)
CA (1) CA3213804A1 (cg-RX-API-DMAC7.html)
TW (1) TWI924837B (cg-RX-API-DMAC7.html)
WO (1) WO2022221143A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
JP2024526203A (ja) * 2021-06-23 2024-07-17 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Wee1阻害剤、及びがんを治療するための方法
WO2024102650A1 (en) * 2022-11-08 2024-05-16 Zeno Management, Inc. Intermittent dosing regimen for azenosertib in treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018286A2 (pt) * 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
WO2020069105A1 (en) 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders of wee1 kinase
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
網路文獻 Zentalis, "Zentalis pharmaceuticals announces promising initial data presented in a late-breaking session at AACR on ZN-c3, its WEE1 inhibitor, in patients with advanced solid tumors" 2021/4/10 https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-announces-promising-initial-data/

Also Published As

Publication number Publication date
CA3213804A1 (en) 2022-10-20
EP4322958A1 (en) 2024-02-21
WO2022221143A1 (en) 2022-10-20
EP4322958A4 (en) 2025-04-09
TW202304455A (zh) 2023-02-01
JP2024517085A (ja) 2024-04-19
AU2022259496A1 (en) 2023-10-12
US20240197743A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
TW202304455A (zh) 用於治療子宮漿液性癌之wee1化合物
US20240197739A1 (en) Combination Comprising Ribociclib and Amcenestrant
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US20240335447A1 (en) Wee1 inhibitor for cancer
TW202333729A (zh) 組合
CN118139625A (zh) Wee1抑制剂和抗cd47抗体的组合
TW202333675A (zh) 用於治療癌症之組合療法之用途
US20250208149A1 (en) Wee1 compound for treating uterine serous carcinoma
US20250205240A1 (en) Combinations
JP2015007143A (ja) 医薬組み合わせ
EP4342475A1 (en) Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
CA2811345C (en) Compound composition for inhalation used for treating asthma
JP2021522345A (ja) 新規なmct4阻害剤及びその使用
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
US20250161276A1 (en) Drug combinations and methods of treating ovarian cancer
CN120379657A (zh) 用于治疗瘦素抵抗性肥胖的选择性下丘脑可渗透的hdac6抑制剂
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
CN117500505A (zh) 用于治疗子宫浆液性癌的wee1化合物
JP2020536846A (ja) Fgfr選択的チロシンキナーゼ阻害剤を含む医薬組成物
CN100455289C (zh) 孟德拉明类抗癌药
CA2828296A1 (en) Method for administration of a gamma secretase inhibitor
TW202519221A (zh) Wee1抑制劑及pkmyt1抑制劑之組合
HK40103578B (en) Egfr inhibitor for the treatment of head and neck cancer
CN114787151A (zh) 喹唑啉衍生物或其盐、或其药物组合物的用途